E

Eventide

North America, New Jersey, United States, Little Ferry

Description

Digital Audio Processing Products

Investor Profile

Eventide has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 2 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series E rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Genetics, Health Care.

Stage Focus

  • Series B (50%)
  • Series E (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Genetics
  • Health Care
  • Information Technology
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Eventide frequently co-invest with?

SV Health Investors
North America, Massachusetts, United States, Boston
Co-Investments: 2
CA
North America, Massachusetts, United States, Boston
Co-Investments: 1
Leerink Partners
North America, Massachusetts, United States, Boston
Co-Investments: 1
Atlas Venture
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Alta Partners
North America, Mississippi, United States, Jackson
Co-Investments: 1
Brace Pharma
North America, Maryland, United States, Rockville
Co-Investments: 1
Citadel
North America, Florida, United States, Miami
Co-Investments: 2
Morningside Venture Partners
North America, New York, United States, New York
Co-Investments: 1
Clarus Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Aisling Capital
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by Eventide?

Sutro Biopharma

South San Francisco, California, United States

Sutro Biopharma develops protein therapeutics by using OCFS protein synthesis technology.

BiotechnologyInformation TechnologyMedical
Series EJul 26, 2018
Amount Raised: $85,400,000
Avrobio

Cambridge, Massachusetts, United States

Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.

BiotechnologyGeneticsHealth Care
Series BFeb 1, 2018
Amount Raised: $60,000,000